TEL AVIV, Israel, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter of 2013 and will host a corporate update conference call on Thursday, February 13, 2014.
|
Conference Call & Webcast |
|
|
Thursday, February 13, 2014 @ 8:30am Eastern Time/5:30am Pacific Time |
|
Domestic: |
855-469-0611 |
|
International: |
484-756-4341 |
|
Passcode: |
34670631 |
|
Webcast: |
www.alcobra-pharma.com |
|
|
|
|
Replays |
|
|
Domestic: |
855-859-2056 |
|
International: |
404-537-3406 |
|
Passcode: |
34670631 |
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MG01CI, to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts:
LifeSci Advisors, LLC
Michael Rice
646-597-6979
mrice@lifesciadvisors.com
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
debbie@alcobra-pharma.com
